Brief: Angion And Vifor Pharma Report Topline Results From Phase 3 Trial Of Ang-3777 In Kidney Transplant Patients At Risk For Delayed Graft Function

Elicio Therapeutics

27/10/2021 24:06

Oct 26 (Reuters) - Angion Biomedica Corp  ANGN.O :
    * ANGION AND VIFOR PHARMA REPORT TOPLINE RESULTS FROM PHASE
3
TRIAL OF ANG-3777 IN KIDNEY TRANSPLANT PATIENTS AT RISK FOR
DELAYED GRAFT FUNCTION
    * ANGION BIOMEDICA CORP - EXPECTS TO REPORT CASH AND CASH
EQUIVALENTS AS OF SEPTEMBER 30, 2021 TOTALING APPROXIMATELY $100
MILLION
    * ANGION BIOMEDICA CORP - OVERALL SAFETY PROFILE OF ANG-3777
IN
THIS TRIAL WAS CONSISTENT WITH OVERALL EXPERIENCE IN ITS
CLINICAL DEVELOPMENT PROGRAM
    * ANGION BIOMEDICA CORP - PHASE 3 TRIAL OF ANGION'S ANG-3777
DID
NOT DEMONSTRATE A STATISTICALLY SIGNIFICANT DIFFERENCE FROM
PLACEBO ON PRIMARY ENDPOINT
    * ANGION BIOMEDICA CORP - ANG-3777 DEMONSTRATED AN
INCONSISTENT
BENEFIT ON KEY SECONDARY ENDPOINTS
    * ANGION BIOMEDICA - BASED ON PHASE 3 DATA, NOT EXPECTED
THERE IS
SUFFICIENT EVIDENCE TO SUPPORT AN INDICATION IN STUDIED DGF
POPULATION FOR ANG-3777

Source text for Eikon:  ID:nGNX2gRz73 
Further company coverage:  ANGN.O 

 ((Reuters.Briefs@thomsonreuters.com;))